Insulin degludec + liraglutide
Insulin degludec + liraglutide has been studied in 11 papers since 2021: 2 trials and 3 observational studies in people, 1 in cells, 4 reviews; 5 in the past year. It is an approved medicine.
See all 11 papers on insulin degludec + liraglutide
At a glance
Independent labs found the same change in people. 4 independent labs in 2 countries; 25 trials, 2 about aging, 6 with no results posted.
“fat-free mass (+ 3.17 kg/m), body cell mass (+ 7.82 kg/m), phase angle (+ 1.75°), and basal metabolic rate (+ 217.6 kcal) all increased (p < 0.001)”
2 of its findings point the other way.
- 4 independent labs in 2 countries
- 2 findings against
- 25 trials, 2 about aging, 6 with no results posted
- Funders: Novo Nordisk and 1 more
- 5 of 16 findings with company ties
- Human trial2
- Humans3
- In silico1
Studies in people
2 studies gave insulin degludec + liraglutide to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
| Trialsix months | 24 people12 women, 23 menmean age, 81.4 yearsPatients who replaced their pre-existing hypoglycemic therapeutic regimen with a flexibly-timed single daily dose of degludeg and liraglutide fixed combination | Aging and disease, Apr 1, 2023 | |
up: Improves DTSQ11.08 (95% CI 7.13–15.02) down: Decreases HbA1c-0.58 (95% CI -1.08 to -0.08) down: Decreases TNF-alpha-1.83 (95% CI -3.12 to -0.54) | Trial6 months | 35 peopleBoth≥ 75 yearsOlder adults; type 2 diabetes | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, Oct 19, 2021 |
What did studies of insulin degludec + liraglutide find?
12Studies of insulin degludec + liraglutide measured 12 outcomes; the most studied are HbA1c (5 studies) and body weight (2).
HbA1c
downin humans5
5 studies
HbA1c
downin humans5
Insulin degludec + liraglutide decreases HbA1c in humans (frail older adults with T2DM) (7.29% to 7.05%).
Human trialfrail older adults with T2DM6 monthsn = 36
Insulin degludec + liraglutide decreases HbA1c in humans (type 2 diabetes) (-0.58 (95% CI -1.08 to -0.08)).
Human trialtype 2 diabetes6 monthsn = 35
Insulin degludec + liraglutide is linked with lower HbA1c in humans (type 2 diabetes) (-1.08% (SD 1.87, p < 0.001)).
Humanstype 2 diabetes180 daysn = 3,062
Insulin degludec + liraglutide is linked with lower HbA1c in humans (older adults with T2DM on insulin therapy).
Humansolder adults with T2DM on insulin therapy6 monthsn = 96
Insulin degludec + liraglutide decreases HbA1c in humans (real-world head-to-head studies in adults with type 2 diabetes).
Reviewreal-world head-to-head studies in adults with type 2 diabetes
Body weight
downin humans2
2 studies
Body weight
downin humans2
Insulin degludec + liraglutide decreases body weight in humans (frail older adults with T2DM) (-2.6 kg).
Human trialfrail older adults with T2DM6 monthsn = 36
Insulin degludec + liraglutide decreases body weight in humans (real-world head-to-head studies in adults with type 2 diabetes).
Reviewreal-world head-to-head studies in adults with type 2 diabetes
Alistipes
upin humans1
1 study
Alistipes
upin humans1
Insulin degludec + liraglutide increases Alistipes in responders.
Human trialin responderssix monthsn = 13
Insulin degludec + liraglutide increases Alistipes in humans (responders with decreased HbA1c) (p=0.013).
Human trialresponders with decreased HbA1cgut6 monthsn = 13
Treatment-emergent adverse events
upin humans1OR 1.69
1 study
Treatment-emergent adverse events
upin humans1OR 1.69
Insulin degludec + liraglutide increases treatment-emergent adverse events in humans (compared to IDegAsp in type 2 diabetes) (OR 1.69, 95% CI 1.08-2.65).
Reviewcompared to IDegAsp in type 2 diabetes
Daily insulin dose
downin humans1
1 study
Daily insulin dose
downin humans1
Insulin degludec + liraglutide is linked with lower daily insulin dose in humans (type 2 diabetes) (-4.95 U/day (SD 21.93, p < 0.001)).
Humanstype 2 diabetes180 daysn = 3,062
insulin resistance
downin humans1
1 study
insulin resistance
downin humans1
Insulin degludec + liraglutide decreases insulin resistance in humans (frail older adults with T2DM) (42.39 to 32.84).
Human trialfrail older adults with T2DM6 monthsn = 36
Fat-free mass
upin humans1
1 study
Fat-free mass
upin humans1
Insulin degludec + liraglutide increases fat-free mass in humans (frail older adults with T2DM) (+3.17 kg/m).
Human trialfrail older adults with T2DM6 monthsn = 36
Level 2 hypoglycemia
downin humans1
1 study
Level 2 hypoglycemia
downin humans1
Insulin degludec + liraglutide is linked with lower level 2 hypoglycemia in humans (older adults with T2DM on insulin therapy) (IR 0.04, 95 % CI 0.01-0.32, p < 0.001).
Humansolder adults with T2DM on insulin therapy3 monthsn = 96
Level 1 hypoglycemia
downin humans1
1 study
Level 1 hypoglycemia
downin humans1
Insulin degludec + liraglutide is linked with lower level 1 hypoglycemia in humans (older adults with T2DM on insulin therapy) (IR 0.08, 95 % CI 0.02-0.34, p < 0.001).
Humansolder adults with T2DM on insulin therapy6 monthsn = 96
Cognitive function
upin humans1
1 study
Cognitive function
upin humans1
Insulin degludec + liraglutide improves cognitive function in humans (type 2 diabetes) (p = 0.02).
Human trialtype 2 diabetes6 monthsn = 35
TNF-alpha
downin humans1
1 study
TNF-alpha
downin humans1
Insulin degludec + liraglutide decreases TNF-alpha in humans (type 2 diabetes) (-1.83 (95% CI -3.12 to -0.54)).
Human trialtype 2 diabetes6 monthsn = 35
DTSQ
upin humans1
1 study
DTSQ
upin humans1
Insulin degludec + liraglutide improves DTSQ in humans (type 2 diabetes) (11.08 (95% CI 7.13–15.02)).
Human trialtype 2 diabetes6 monthsn = 35
Has insulin degludec + liraglutide been tested in people?
2 of 25 about agingYes: 2 trials and 3 observational studies in people have been published, and 25 trials are registered.
About aging
Phase 3Completed
Phase 3Completed
Approved
Sep 18, 2014Diabetes Mellitus, Type 2, Diabetes Mellitus
Nov 21, 2016Diabetes Mellitus, Type 2
Repurposing
Phase 3Completed1 trial
Who is developing insulin degludec + liraglutide?
1 company: Tonghua Dongbao Pharmaceutical.
- Companies
- Tonghua Dongbao PharmaceuticalPhase 3type 2 diabetes
Trial sponsors
Company19 trialsPhase 38,947 people
Tonghua Dongbao Pharmaceutical
Company2 trialsPhase 3554 people
1 trialPhase 4100 people
Population Health Research Institute
1 trialPhase 3159 people
1 trialPhase 3145 people
Hospital Universitario San Ignacio
1 trialPhase 366 people